Gilead Sciences (Foster City, CA) Grants Intellectual Property Rights For Tenofovir Topical Gel To The International Partnership For Microbicides And CONRAD

FOSTER CITY, Calif. & SILVER SPRING, Md. & ARLINGTON, Va.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD), the International Partnership for Microbicides (IPM) and CONRAD today announced an agreement under which Gilead has granted rights to IPM and CONRAD to develop, manufacture and, if proven efficacious, arrange for distribution in resource-limited countries of tenofovir as a microbicide to prevent infection with HIV, the virus that causes AIDS.